A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's…
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.